GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LadRx Corp (STU:CX5) » Definitions » Net Income Including Noncontrolling Interests

LadRx (STU:CX5) Net Income Including Noncontrolling Interests : €0.35 Mil (TTM As of Dec. 2023)


View and export this data going back to 1986. Start your Free Trial

What is LadRx Net Income Including Noncontrolling Interests?

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

LadRx's Net Income Including Noncontrolling Interests for the three months ended in Dec. 2023 was €-0.79 Mil. Its Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Dec. 2023 was €0.35 Mil.

LadRx Net Income Including Noncontrolling Interests Historical Data

The historical data trend for LadRx's Net Income Including Noncontrolling Interests can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LadRx Net Income Including Noncontrolling Interests Chart

LadRx Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Income Including Noncontrolling Interests
Get a 7-Day Free Trial Premium Member Only Premium Member Only -6.45 -5.51 -11.66 -3.97 0.37

LadRx Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Net Income Including Noncontrolling Interests Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.89 -1.00 2.91 -0.77 -0.79

LadRx Net Income Including Noncontrolling Interests Calculation

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.35 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LadRx Net Income Including Noncontrolling Interests Related Terms

Thank you for viewing the detailed overview of LadRx's Net Income Including Noncontrolling Interests provided by GuruFocus.com. Please click on the following links to see related term pages.

LadRx (STU:CX5) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LadRx Corp (STU:CX5) » Definitions » Net Income Including Noncontrolling Interests
Comparable Companies
NVIVQ CMRA GSTC AGTX SQZB GRI EVLO INM ENDV HSTO OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB XBRU:ARGX BNTX
Traded in Other Exchanges
LADX:USA
Address
11726 San Vicente Boulevard, Suite 650, Los Angeles, CA, USA, 90049
Website
https://www.ladrxcorp.com
LadRx Corp operates as a biopharmaceutical research and development company in the healthcare sector of the United States. It is focused on the discovery, research, and clinical development of novel anti-cancer drug candidates that employ novel linker technologies to enhance the accumulation and release of cytotoxic anti-cancer agents at the tumor. The company develops Aldoxorubicin, which is meant to cure soft tissue sarcoma, a kind of tumor. It also develops Arimoclomol which is in development in Niemann Pick disease Type C (NPC) and Gaucher disease.

LadRx (STU:CX5) Headlines

No Headlines